Eilean Therapeutics LLC has acquired Ness Therapeutics Inc in an equity transaction, gaining access to their leading PTPN2 inhibitors for cancer immunotherapy. These compounds exhibit potent activity against PTPN2/PTPN1, high selectivity, oral bioavailability, and safety. They sensitize tumor cells to IFNγ, potentially enhancing cancer treatment efficacy.
Eilean Therapeutics LLC, a biopharmaceutical firm specializing in the discovery and development of cutting-edge small molecule inhibitors to combat resistance mechanisms in various cancers, has announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction. Ness is known for its development of top-tier PTPN2 inhibitors, offering an immuno-oncological therapy with enhanced safety and tolerability.
PTPN2, also referred to as T cell protein tyrosine phosphatase (TC-PTP), plays a crucial role as a negative regulator of the JAK-STAT pathway, particularly in hematopoietic and placental cells. Inhibition of PTPN2 holds promise as a therapeutic approach to enhance IFNγ signaling, thereby potentially improving the effectiveness of cancer immunotherapy.
Ness’ lead compounds exhibit exceptional sub-nanomolar inhibitory activity against PTPN2/PTPN1 and exceptional selectivity (> 1000-fold) against other phosphatases. These compounds boast high oral bioavailability and a favorable safety profile. Moreover, they have demonstrated the ability to sensitize tumor cells to IFNγ, effectively suppressing their growth.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.